Comparative review of tetracycline antibiotics versus glycylcycline antibiotics in the management of complicated skin and soft tissue infections
Keywords:
Complicated skin and soft tissue infections (cSSTIs); tetracycline; glycylcycline; antibiotic resistance; clinical efficacy; individualized treatmentAbstract
Complicated skin and soft tissue infections (cSSTIs) comprise a variety of infections affecting the dermis, subcutaneous tissue, fascia, or muscle. These infections frequently require hospitalization and systemic antibiotic therapy. They often arise from a variety of bacteria, including both Gram-positive and Gram-negative strains. This includes multidrug-resistant organisms like methicillin-resistant Staphylococcus aureus (MRSA) and Gram-negative bacilli producing extended-spectrum beta-lactamase (ESBL). Due to increasing concern surrounding antimicrobial resistance, it is essential to choose the right antibiotic regimen. This review compares the efficacy, pharmacology, and clinical applicability of tetracyclines, specifically doxycycline and minocycline, with the glycylcycline tigecycline in managing cSSTIs. While tetracyclines remain valuable for mild-to-moderate infections due to their oral availability and effectiveness against MRSA, their utility is limited by rising resistance and narrower activity against Gram-negative organisms. Tigecycline, a synthetic derivative of minocycline, was developed to overcome common tetracycline resistance mechanisms and shows efficacy against an expanded spectrum of bacteria, including drug-resistant Gram-positive and Gram-negative strains. The review explores evidence from clinical trials, pharmacokinetics and safety concerns to support rational antibiotic selection. It highlights that although tigecycline is a potent option for severe, polymicrobial, or resistant infections, its use should be cautious due to mortality risks and IV-only formulation. Tetracyclines, meanwhile, remain a cost-effective and well-tolerated choice for less complex cases, underscoring the importance of individualized treatment strategies.
References
Zervos MJ, Freeman K, Vo L, Haque N, Pokharna H, Raut M, et al. Epidemiology and outcomes of complicated skin and soft tissue infections in hospitalized patients. J Clin Microbiol. 2012;50(2):238-45. https://doi.org/10.1128/JCM.05817-11
Merlino JI, Malangoni MA. Complicated skin and soft-tissue infections: diagnostic approach and empiric treatment options. Cleve Clin J Med. 2007;74 Suppl 4:S21-8.
Leong HN, Kurup A, Tan MY, Kwa AL, Liau KH, Wilcox MH. Management of complicated skin and soft tissue infections with a special focus on the role of newer antibiotics. Infect Drug Resist. 2018;11:1959-74. https://doi.org/10.2147/IDR.S172366
Harch SA, MacMorran E, Tong SY, Holt DC, Wilson J, Athan E, et al. High burden of complicated skin and soft tissue infections in the Indigenous population of Central Australia due to dominant Panton Valentine leucocidin clones ST93-MRSA and CC121-MSSA. BMC Infect Dis. 2017;17. https://doi.org/10.1186/s12879-017-2460-3
Sacchidanand S, Penn RL, Embil JM, Campos ME, Curcio D, Ellis-Grosse E, et al. Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: results from a phase 3, randomized, double-blind trial. Int J Infect Dis. 2005;9(5):251-61. https://doi.org/10.1016/j.ijid.2005.05.003
Gibbons JA, Smith HL, et al. Antimicrobial stewardship in the treatment of skin and soft tissue infections. Am J Infect Control. 2017;45(11):1203-7. https://doi.org/10.1016/j.ajic.2017.05.013
Chopra I, Roberts M. Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev. 2001;65(2):232-60. https://doi.org/10.1128/MMBR.65.2.232-260.2001
Grossman TH. Tetracycline antibiotics and resistance. Cold Spring Harb Perspect Med. 2016;6(4):a025387. https://doi.org/10.1101/cshperspect.a025387
Curcio D. Off-label use of antibiotics in hospitalized patients: focus on tigecycline. J Antimicrob Chemother. 2009;64(6):1344-6. https://doi.org/10.1093/jac/dkp342
Nguyen F, Starosta AL, Arenz S, Sohmen D, Dönhöfer A, Wilson DN. Tetracycline antibiotics and resistance mechanisms. Biol Chem. 2014;395(5):559-75.
Rusu A, Buta EL. The development of third-generation tetracycline antibiotics and new perspectives. Pharmaceutics. 2021;13(12):2085. https://doi.org/10.3390/pharmaceutics13122085
Chukwudi CU. rRNA binding sites and the molecular mechanism of action of the tetracyclines. Antimicrob Agents Chemother. 2016;60(8):4433-41.
Streit JM, Jones RN, Sader HS, Fritsche TR. Assessment of pathogen occurrences and resistance profiles among infected patients in the intensive care unit: report from the SENTRY Antimicrobial Surveillance Program (North America, 2001). Int J Antimicrob Agents. 2004;24(2):111-8. https://doi.org/10.1016/j.ijantimicag.2003.12.019
Chopra I. Glycylcyclines: third-generation tetracycline antibiotics. Curr Opin Pharmacol. 2001;1(5):464-9.
Stein GE, Babinchak T. Tigecycline: an update. Diagn Microbiol Infect Dis. 2013;75(4):331-6. https://doi.org/10.1016/j.diagmicrobio.2012.12.004
Gallagher JC. Omadacycline: a modernized tetracycline. Clin Infect Dis. 2019;69(Suppl 1):S1-5.
Qiao Y, Chen Y, Wang Q, Liu J, Guo X, Gu Q, et al. Safety profiles of doxycycline, minocycline, and tigecycline in pediatric patients: a real-world pharmacovigilance analysis based on the FAERS database. Front Pharmacol. 2024;15:1413944. https://doi.org/10.3389/fphar.2024.1413944
Shutter MC, Akhondi H. Tetracycline. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 [updated 2023 Jun 5]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK549905/
Bhatia N, Del Rosso J, Stein Gold L, Lain E, Draelos ZD, Sidgiddi S. Efficacy, safety, and tolerability of oral DFD-29, a low-dose formulation of minocycline, in rosacea: two phase 3 randomized clinical trials. JAMA Dermatol. 2025;161(5):499-507. https://doi.org/10.1001/jamadermatol.2024.6542
Guay DR. Oritavancin and tigecycline: investigational antimicrobials for multidrug-resistant bacteria. Pharmacotherapy. 2004;24(1):58-68. https://doi.org/10.1592/phco.24.1.58.34808
Greer ND. Tigecycline (Tygacil): the first in the glycylcycline class of antibiotics. Proc (Bayl Univ Med Cent). 2006;19(2):155-61. https://doi.org/10.1080/08998280.2006.11928154
Lauf L, Ozsvár Z, Mitha I, et al. Phase 3 study comparing tigecycline and ertapenem in patients with diabetic foot infections with and without osteomyelitis. Diagn Microbiol Infect Dis. 2014;78(4):469-80.
Kechagias KS, Chorepsima S, Triarides NA, Falagas ME. Tigecycline for the treatment of patients with Clostridium difficile infection: an update of the clinical evidence. Eur J Clin Microbiol Infect Dis. 2020;39(6):1053-8. https://doi.org/10.1007/s10096-019-03756-z
Li W, Atkinson GC, Thakor NS, Allas U, Lu CC, Chan KY, et al. Mechanism of tetracycline resistance by ribosomal protection protein Tet(O). Nat Commun. 2013;4:1477. https://doi.org/10.1038/ncomms2470
Korczak L, Majewski P, Iwaniuk D, Sacha P, Matulewicz M, Wieczorek P, et al. Molecular mechanisms of tigecycline-resistance among Enterobacterales. Front Cell Infect Microbiol. 2024;14:1289396. https://doi.org/10.3389/fcimb.2024.1289396
US Food and Drug Administration. FDA drug safety communication: FDA warns of increased risk of death with IV antibacterial Tygacil (tigecycline) and approves new boxed warning [Internet]. Silver Spring (MD): FDA; 2013 Sep 27 [cited 2025 May 13]. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-warns-increased-risk-death-iv-antibacterial-tygacil-tigecycline
Finch RG, Greenwood D, Norrby SR, Whitley RJ. Antibiotic and chemotherapy. 9th ed. Edinburgh: Saunders Elsevier; 2010.
Mukker JK, Singh RP, Derendorf H. Determination of atypical nonlinear plasma-protein-binding behavior of tigecycline using an in vitro microdialysis technique. J Pharm Sci. 2014;103(3):1013-9. https://doi.org/10.1002/jps.23872
Passarell JA, Meagher AK, Liolios K, Cirincione BB, Van Wart SA, Babinchak T, et al. Exposure-response analyses of tigecycline efficacy in patients with complicated intra-abdominal infections. Antimicrob Agents Chemother. 2008;52(1):204-10. https://doi.org/10.1128/AAC.00813-07
Nathwani D. Tigecycline: clinical evidence and formulary positioning. Int J Antimicrob Agents. 2005;25(3):185-92. https://doi.org/10.1016/j.ijantimicag.2004.11.006
Curcio D. Skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus: role of tigecycline. Clin Infect Dis. 2011;52(12):1468-9. https://doi.org/10.1093/cid/cir192
Hosgor-Limoncu M. Is tigecycline drug of choice for cIAI and cSSTI? Int J Clin Pract. 2013;67(6):492-3. https://doi.org/10.1111/ijcp.12169
Bassetti M, Eckmann C, Bodmann KF, Dupont H, Heizmann WR, Montravers P, et al. Prescription behaviours for tigecycline in real-life clinical practice from five European observational studies. J Antimicrob Chemother. 2013;68 Suppl 2:ii5-14. https://doi.org/10.1093/jac/dkt140
Ibrahim MM, Abuelmatty AM, Mohamed GH, Nasr MA, Hussein AK, Ebaed MED, et al. Best tigecycline dosing for treatment of infections caused by multidrug-resistant pathogens in critically ill patients with different body weights. Drug Des Devel Ther. 2018;12:4171-9. https://doi.org/10.2147/DDDT.S181834
Yahav D, Lador A, Paul M, Leibovici L. Efficacy and safety of tigecycline: a systematic review and meta-analysis. J Antimicrob Chemother. 2011;66(9):1963-71. https://doi.org/10.1093/jac/dkr242
Liu Q, He D, Wang L, Wu Y, Liu X, Yang Y, et al. Efficacy and safety of antibiotics in the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections: a systematic review and network meta-analysis. Antibiotics (Basel). 2024;13(9):866. https://doi.org/10.3390/antibiotics13090866
NeVille-Swensen M, Clayton M. Outpatient management of community-associated methicillin-resistant Staphylococcus aureus skin and soft tissue infection. J Pediatr Health Care. 2011;25(5):308-15. https://doi.org/10.1016/j.pedhc.2010.05.005
Bhambri S, Kim G. Use of oral doxycycline for community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) infections. J Clin Aesthet Dermatol. 2009;2(4):45-50.
Wallace RJ Jr, Brown-Elliott BA, Crist CJ, Mann L, Wilson RW. Comparison of the in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline, and doxycycline against isolates of nontuberculous mycobacteria. Antimicrob Agents Chemother. 2002;46(10):3164-7. https://doi.org/10.1128/AAC.46.10.3164-3167.2002
Sun J, Chen C, Cui CY, Zhang Y, Liu X, Cui ZH, et al. Plasmid-encoded tet(X) genes that confer high-level tigecycline resistance in Escherichia coli. Nat Microbiol. 2019;4(9):1457-64. https://doi.org/10.1038/s41564-019-0496-4
He T, Wang R, Liu D, Walsh TR, Zhang R, Lv Y, et al. Emergence of plasmid-mediated high-level tigecycline resistance genes in animals and humans. Nat Microbiol. 2019;4(9):1450-6. https://doi.org/10.1038/s41564-019-0445-2
Feng J, Su M, Li K, Ma J, Li R, Bai L, et al. Extensive spread of tet(X4) in multidrug-resistant Escherichia coli of animal origin in western China. Vet Microbiol. 2022;269:109420. https://doi.org/10.1016/j.vetmic.2022.109420
Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJ, Gorbach SL, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014;59(2):e10-52. https://doi.org/10.1093/cid/ciu296
Bidell MR, Lodise TP. Use of oral tetracyclines in the treatment of adult outpatients with skin and skin structure infections: focus on doxycycline, minocycline, and omadacycline. Pharmacotherapy. 2021;41(11):915-31. https://doi.org/10.1002/phar.2625
Chuang YC, Chang CM, Aradhya S, Nagari B, Pai V, Dartois N, et al. Efficacy and safety of tigecycline monotherapy compared with vancomycin-aztreonam in the treatment of complicated skin and skin structure infections in patients from India and Taiwan. J Microbiol Immunol Infect. 2011;44(2):116-24. https://doi.org/10.1016/j.jmii.2010.04.002
Yaghoubi S, Zekiy AO, Krutova M, et al. Tigecycline antibacterial activity, clinical effectiveness, and mechanisms and epidemiology of resistance: narrative review. Eur J Clin Microbiol Infect Dis. 2022;41(7):1003-22. https://doi.org/10.1007/s10096-020-04121-1
Chopra I. New developments in tetracycline antibiotics: glycylcyclines and tetracycline efflux pump inhibitors. Drug Resist Updat. 2002;5(3-4):119-25. https://doi.org/10.1016/S1368-7646(02)00051-1
Burgos RM, Rodvold KA. Omadacycline: a novel aminomethylcycline. Infect Drug Resist. 2019;12:1895-915. https://doi.org/10.2147/IDR.S171352
Ministry of Health Malaysia. National antimicrobial guideline (NAG). 4th ed. [Internet]. Putrajaya: Ministry of Health Malaysia; 2024 [cited 2025 May 13]. Available from: https://sites.google.com/moh.gov.my/nag/home
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Nurin Zarifah Binti Rosairie , Nur Ain Syazwani Binti Abdul Rahman , Nuranis Faatihah Binti Borhan , Yasmin Syamini Binti Zarin

This work is licensed under a Creative Commons Attribution 4.0 International License.



